Odyssey Therapeutics (NASDAQ:ODTX) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Odyssey Therapeutics (NASDAQ:ODTX) to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

ODTX has been the subject of a number of other reports. Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a research report on Saturday, May 16th. TD Cowen assumed coverage on Odyssey Therapeutics in a research report on Tuesday. They set a “buy” rating for the company. Wedbush initiated coverage on Odyssey Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $30.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Odyssey Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $26.00 target price for the company. Finally, Oppenheimer initiated coverage on Odyssey Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $40.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Odyssey Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Odyssey Therapeutics Price Performance

Shares of NASDAQ:ODTX opened at $17.00 on Wednesday. Odyssey Therapeutics has a 12-month low of $15.35 and a 12-month high of $20.30.

Insider Buying and Selling

In other news, Director Shelley Chu bought 11,111 shares of the company’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $18.00 per share, with a total value of $199,998.00. Following the transaction, the director directly owned 11,111 shares in the company, valued at $199,998. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dimension Capital Ii, L.P. bought 1,111,111 shares of the company’s stock in a transaction on Friday, May 8th. The stock was purchased at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director owned 3,333,516 shares in the company, valued at $60,003,288. This represents a 50.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 4,183,777 shares of company stock worth $75,319,986 over the last 90 days.